Here are three observations:
1. The market’s value is positioned to hit $3.9 billion by 2025.
2. The increasing patient demand for noninvasive surgery, rising number of bone-related issues and growing number of investment opportunities will spur market growth.
3. Key market players include ITO, Isto Biologics, Harvest Technologies, Ember Therapeutics, DJO Finance, DePuy Synthes, Bioventus, Arthrex, Orthofix, Medtronic, Altis Biologics, Ossatec Benelux, Regen Lab, Stryker and Zimmer Biomet.
More articles on devices:
Tissue Regenix proposes acquisition of CellRight Technologies: 4 notes
Zimmer Biomet, Spineway, Implanet & more: 12 device company key notes
Global vertebroplasty, kyphoplasty market gains steam with boost in osteoporosis: 8 observations
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
